AstraZeneca's COVID-19 Vaccine Is World’s Leading Candidate and May Deliver Results Earlier, Says WHO
By HospiMedica International staff writers Posted on 29 Jun 2020 |
Illustration
The experimental COVID-19 vaccine from AstraZeneca (Cambridgeshire, England) is possibly the world’s leading candidate and the most advanced in terms of development, according to the chief scientist of the World Health Organization (WHO).
“Certainly in terms of how advanced they are, the stage at which they are, they are I think probably the leading candidate,” WHO chief scientist Soumya Swaminathan told a news conference. “So it’s possible they will have results quite early.”
A report by Reuters has stated that AstraZeneca had already commenced large-scale, mid-stage human trials of the vaccine developed by researchers at University of Oxford and recently signed its 10th supply-and-manufacturing deal. According to Swaminathan, Moderna’s COVID-19 vaccine candidate was “not far behind” that of AstraZeneca and among more than 200 candidates, 15 had entered clinical trials.
“We do know that Moderna’s vaccine is also going to go into phase three clinical trials, probably from the middle of July, and so that vaccine candidate is not far behind,” said Swaminathan. “But I think AstraZeneca certainly has a more global scope at the moment in terms of where they are doing and planning their vaccine trials.”
Swaminathan said that the WHO was in discussions with several Chinese manufacturers, including Sinovac, as well as with Indian researchers on potential vaccines and called for drugmakers to consider collaborating on COVID-19 vaccine trials.
“Certainly in terms of how advanced they are, the stage at which they are, they are I think probably the leading candidate,” WHO chief scientist Soumya Swaminathan told a news conference. “So it’s possible they will have results quite early.”
A report by Reuters has stated that AstraZeneca had already commenced large-scale, mid-stage human trials of the vaccine developed by researchers at University of Oxford and recently signed its 10th supply-and-manufacturing deal. According to Swaminathan, Moderna’s COVID-19 vaccine candidate was “not far behind” that of AstraZeneca and among more than 200 candidates, 15 had entered clinical trials.
“We do know that Moderna’s vaccine is also going to go into phase three clinical trials, probably from the middle of July, and so that vaccine candidate is not far behind,” said Swaminathan. “But I think AstraZeneca certainly has a more global scope at the moment in terms of where they are doing and planning their vaccine trials.”
Swaminathan said that the WHO was in discussions with several Chinese manufacturers, including Sinovac, as well as with Indian researchers on potential vaccines and called for drugmakers to consider collaborating on COVID-19 vaccine trials.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans